Sandbox:Roukoz: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 6: Line 6:
{{familytree | | | | | | | | | C01 | | | | | |C01=Histopathologic examination}}
{{familytree | | | | | | | | | C01 | | | | | |C01=Histopathologic examination}}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | |,|-|-|-|-|-|-|-|-|v|-|-|-|-|.| }}
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }}
{{familytree | | |!| | | | | | | | |!| | | | |!| }}
{{familytree | |D01| | | | | |D02| | | | D03 |D01='''Squamous cell carcinoma'''|D02='''Adenocarcinoma and poorly differntiated carcinoma'''|D03='''Neuroendocrine carcinoma'''}}
{{familytree | | D01 | | | | | | |D02 | | | D03 |D01='''Squamous cell carcinoma'''|D02='''Adenocarcinoma and poorly differntiated carcinoma'''|D03='''Neuroendocrine carcinoma'''}}
{{familytree | | |!| | | | | | | | |!| | | | |!| }}
{{familytree | | |!| | | | | | | | |!| | | | |!| }}
{{familytree | |E01| | | | | | |E02 | | |boxstyle=text-align: left; |E03| |E01=Additional tests specific to location of metastasis|E02=Gender specific tests|E03=• Octreoscan<br> • Plasma chromogranin A}}
{{familytree | |E01| | | | | | |E02 | | |boxstyle=text-align: left; |E03| |E01=Additional tests specific to location of metastasis|E02=Gender specific tests|E03=• Octreoscan<br> • Plasma chromogranin A}}

Revision as of 18:51, 10 October 2018

 
 
 
 
 
 
 
 
Tumor of unknown primary origin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Full medical history and physical exam
• Basic blood and bichemical analysis
• CT scan of chest, abdomen, and pelvis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histopathologic examination
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Squamous cell carcinoma
 
 
 
 
 
Adenocarcinoma and poorly differntiated carcinoma
 
 
 
Neuroendocrine carcinoma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional tests specific to location of metastasis
 
 
 
 
 
 
Gender specific tests
 
 
• Octreoscan
• Plasma chromogranin A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{{{F01}}}
 
{{{F02}}}
 
{{{F03}}}
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Male
• PSA
• aFP
• BHCG
 
 
 
Female
• Mammography
• Ultrasound or pelvic CT